TAE684 (NVP-TAE684)

TAE684 (NVP-TAE684)は、3nMのIC50による強力で選択的なALKキナーゼ阻害剤です。

5 5 4レビュー 10製品表彰状
価格 在庫  
USD 201 In stock
USD 338 In stock
USD 365 In stock
USD 970 In stock
USD 2356 In stock

TAE684 (NVP-TAE684) 化学構造
分子量: 614.2



Quality Control & MSDS


  • Compare ALK Inhibitors
  • 研究分野
  • TAE684 (NVP-TAE684)のメカニズム



情報 TAE684 (NVP-TAE684)は、3nMのIC50による強力で選択的なALKキナーゼ阻害剤です。
目標 ALK
IC50 3 nM [1]
In vitro試験 TAE684 does not exhibit significant cross-reactivity against other kinases. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM. Molecular modeling reveals that L258 may be one of the major kinase-selectivity determinants for TAE684. TAE684 treatment results in a rapid and sustained inhibition of phosphorylation of NPM-ALK. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. [1] TAE684 markedly overcomes Crizotinib-resistance in H3122 CR cells, harboring the fusion oncogene EML4-ALK, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis.[2] Neurite outgrowth induced by expression of the mALK R1279Q mutant could be completely inhibited by TAE684 at 30 nM. [3]
In vivo試験 After 4 weeks of treatment with TAE684 at 3 and 10 mg/kg, there is a significant delay in lymphoma development and 100- to 1,000-fold reduction in luminescence signal, without any signs of compound- or disease-related toxicity in Karpas-299 lymphoma model. TAE684 treatment also induces disease regression in established Karpas-299 lymphomas and down-regulates CD30 expression. [1] TAE684 also shows impressive antitumor activity against H3122 CR xenograft tumors. [2] Furthermore, treatment with TAE684 improves the rough eye phenotype of both ALK mutants, especially that seen with ALKR1275Q, whereas Crizotinib has little effect on either phenotype. [3]

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

In vitro Enzyme Assays. All in vitro enzyme assays are done at Upstate Biotechnology with the exception of InsR and IGF-1R. To determine the IC50 of TAE684 against InsR and IGF-1R a homogeneous time-resolved fluorescence assay is performed. ATP (10 mM) and 20 mg/ml biotinylated PolyEY (Glu, Tyr 4:1) are combined with 50 nL of serial dilutions of TAE684 (10-500 nM) and 4 ng of InsR enzyme in the presence of the kinase reaction buffer (20 mM Tris譎Cl, pH 7.5/10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA). Assays are incubated for 1 hour at ambient temperature. Reactions are terminated by adding 10 mL of the detection solution containing 50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/mL Eu3+ cryptate-labeled anti-phosphotyrosine antibody Mab PT66-K, and 5 mg/mL Streptavidin-XLent. The reaction is incubated for half an hour, and fluorescence signals are read on Analyst GT.

細胞アッセイ: [1]

細胞系 Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, Bcr-Abl, or TEL-kinase fusion constructs.
濃度 1 nM-10 μM
処理時間 2–3 days
方法 Cells are seeded in 384-well plates (2.5×104 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2–3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.

動物実験: [1]

動物モデル Karpas-299 xenografts are established in 4- to 6-week old female Fox Chase SCIDBeige mice.
製剤 Resuspended in 10% 1-methyl-2-pyrrolidinone/90% polyethylene glycol 300 solution
投薬量 1, 3, and 10 mg/kg
管理 Once daily by oral gavage for 3 weeks



Download TAE684 (NVP-TAE684) SDF
分子量 614.2


CAS No. 761439-42-3
別名 N/A
溶解度 (25°C)
  • DMSO 3 mg/mL
  • 水 <1 mg/mL
  • エタノール <1 mg/mL
保管 2年 -20°C
6月-80°Cin DMSO
化学名 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine


カスタマーレビュー (4)

Click to enlarge
Source Neoplasia Vol. 13, No. 8, 2011. TAE684 (NVP-TAE684) purchased from Selleck
Method Western blot
Cell Lines H-1299 cells
Concentrations 0.03-1uM
Incubation Time
Results Treatment efficiently inhibited the cell proliferation and phospho-Y1604 ALK expression of H694R or E1384K mutant ALK, but also to a degree higher than that of wild-type ALK.

Click to enlarge
Source Neoplasia Vol. 13, No. 8, 2011 . TAE684 (NVP-TAE684) purchased from Selleck
Method Xenograft
Cell Lines mice
Incubation Time 4 weeks
Results Consistently, TAE684 treatment repressed H694R- and E1384K-induced tumor growth compared with DMSO control.

Click to enlarge
Source Neoplasia Vol. 13, No. 8, 2011. TAE684 (NVP-TAE684) purchased from Selleck
Method Cell Proliferation Assay
Cell Lines H-1299 cells
Concentrations 0-3 uM
Incubation Time
Results Treatment efficiently inhibited the cell proliferation and phospho- Y1604 ALK expression of H694R or E1384K mutant ALK, but also to a degree higher than that of wild-type ALK.

Click to enlarge
Source Cancer Res , 2011, 71, 4920-31. TAE684 (NVP-TAE684) purchased from Selleck
Method Western blot
Cell Lines H3122 cells
Concentrations 100 nmol/L
Incubation Time 6 h
Results Figure A shows that the primary adaptors for PI3K activation are IRS1 and IRS2 in H3122 mouse xenografts. Interestingly, treatment with TAE-684 eliminates these interactions, suggesting that ALK signals to PI3K via IRS2 and IRS1. This is consistent with previous reports suggesting that NPM-ALK signals to PI3K via IRS proteins. The finding that IRS proteins were utilized to activate PI3K suggested that these cells might activate PI3K in response to IGF-I. Indeed, treatment of H3122 cells with IGF-I, but not EGF or HGF, rescued PI3K-AKT signaling with TAE-684 treatment (Fig. B).

製品表彰状 (10)

  • Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. [Wilson TR, et al. Nature 2012;487(7408):505-9]

    PubMed: 22763448
  • MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. [Huang S, et al. Cell 2012;151(5):937-50]

    PubMed: 23178117
  • Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. [Yang X, et al. Cancer Res 2011;71(18):5965-75]

    PubMed: 21775521
  • Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. [Lovly CM, et al. Cancer Res 2011;71(14):4920-31]

    PubMed: 21613408
  • Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. [Davies KD, et al. Clin Cancer Res 2012;18(17):4570-9]

    PubMed: 22919003
  • Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. [Yamada T, et al. Clin Cancer Res 2013;18(13):3592-602]

    PubMed: 22553343
  • Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. [Hyeong Ryul Kim, et al. MOLECULAR ONCOLOGY 2013;7(6):1093-102]

    PubMed: 23993685
  • Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer. [Wang YW, et al. Neoplasia 2011;13(8):704-15]

    PubMed: 21847362
  • Interferon-γ induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages. [Kuss M, et al. J Neurochem 2014;10.1111/jnc.12668]

    PubMed: 24479685
  • Epithelial-mesenchymal transition confers resistance to FGFR inhibitors in gastric cancer cell line [Paulina Grygielewicz, et al. CELON PHARMA 2013;2013]



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related ALK 阻害剤

  • Crizotinib (PF-02341066)

    Crizotinib (PF-02341066) は1種の有効な小分子の卵白の阻害剤の再編人プロテインキナーゼ、 Kiが 4 nM。

  • GSK1838705A

    GSK1838705Aは、IGF-IR、IrとALKのキナーゼ阻害剤で、IC50 がそれぞれ 2.0 nM、 1.6 nMと0.5 nMです。

  • CH5424802

    Alectinib (CH5424802)は高度に選択、有効なアルカリ剤の内服、 IC50 が1.9 nM。

  • AP26113

    AP26113は、強力なALK阻害剤で、ALKFERROS/ROS1FLT3FES/FPSに作用すると、IC50 がそれぞれ0.62 nM、 1.3 nM、 1.9 nM、 2.1 nM 、 3.4 nMです。

  • LDK378


  • AZD3463

    AZD-3463は ALKの新しい阻害剤で、IC50 が 22 nMです。

  • ASP3026

    ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM.

  • Linifanib (ABT-869)

    Linifanib(ABT-869)は、新しい、強力なATP競争的RTK阻害剤で、KDRCSF-1RFlt-1Flt-3に作用するとき、IC50がそれぞれ 4 nM、 3 nM、 3 nM 、3 nMになる。

  • Nintedanib (BIBF 1120)

    Nintedanib (BIBF 1120)は三重血管キナーゼ阻害剤、VEGFR1, VEGFR2, VEGFR3 を作用すると、 IC50 がそれぞれ 34 nM, 5 nM 、 5 nMとなる。Phase 2.

  • BMS-536924

    BMS-536924は、ATP競争的IGF-IRとIR阻害剤で、IC50 がそれぞれ 100 nM と 73 nMです。


Tags: TAE684 (NVP-TAE684)を買う | TAE684 (NVP-TAE684)供給者 | TAE684 (NVP-TAE684)を購入する | TAE684 (NVP-TAE684)費用 | TAE684 (NVP-TAE684)生産者 | オーダーTAE684 (NVP-TAE684) | TAE684 (NVP-TAE684)代理店